Loading...
XNAS
HIND
Market cap2mUSD
Dec 05, Last price  
5.01USD
1D
-1.57%
1Q
-36.98%
Jan 2017
-43.39%
IPO
-66.60%
Name

ReShape Lifesciences Inc

Chart & Performance

D1W1MN
XNAS:HIND chart
P/E
—
P/S
0.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-8.05%
Rev. gr., 5y
-11.91%
Revenues
8m
-7.74%
0000000312,00000292,000786,6601,287,154606,71015,089,00011,299,00013,600,00011,240,0008,678,0008,006,000
Net income
-7m
L-37.38%
-11,215,191-17,690,477-28,575,348-37,874,028-31,929,000-17,347,000-25,997,322-23,460,000-25,781,000-26,129,000-25,499,000-23,360,844-33,817,972-81,151,575-74,207,000-21,630,000-61,933,000-46,214,000-11,387,000-7,130,000
CFO
-4m
L-73.90%
-10,278,090-16,228,123-23,368,510-33,668,613-24,657,223-13,664,607-19,935,434-22,479,369-18,425,729-19,383,663-22,606,040-20,655,793-24,588,208-27,490,170-14,200,000-8,550,000-15,375,000-21,902,000-16,960,000-4,427,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. As of February 27, 2020, it had three company-managed retail treatment centers in California. Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.
URL
https://www.reshapelifesciences.com/obalon/
IPO date
Oct 06, 2016
Employees
40
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT